Purple Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Purple Biotech
PPBT Stock  USD 0.61  0.01  1.00%   
Analyzing historical trends in various income statement and balance sheet accounts from Purple Biotech's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Purple Biotech's valuation are summarized below:
Gross Profit
-62 K
Market Capitalization
6.8 M
Enterprise Value Revenue
33.0832
Earnings Share
(45.90)
There are currently one hundred twenty trending fundamental ratios for Purple Biotech that can be evaluated and compared over time across competitors. All traders should check out Purple Biotech's recent fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 17.9 M in 2026, whereas Enterprise Value is likely to drop slightly above 2.8 M in 2026.

Purple Biotech Total Revenue

0.0

Check Purple Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Purple Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 159.9 K, Interest Expense of 298.6 K or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 92.33, Dividend Yield of 0.088 or PTB Ratio of 0.48. Purple financial statements analysis is a perfect complement when working with Purple Biotech Valuation or Volatility modules.
  
Build AI portfolio with Purple Stock
Check out the analysis of Purple Biotech Correlation against competitors.
For more information on how to buy Purple Stock please use our How to Invest in Purple Biotech guide.

Purple Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets33.1 M42.6 M25.8 M
Slightly volatile
Short and Long Term Debt Total156.5 K164.7 K471.2 K
Slightly volatile
Other Current Liabilities2.3 M2.5 M1.8 M
Slightly volatile
Total Current Liabilities3.8 M4.6 M3.1 M
Slightly volatile
Accounts Payable1.2 M1.7 M967 K
Slightly volatile
Cash8.4 M8.5 M6.4 M
Slightly volatile
Cash And Short Term Investments18.6 M9.8 M13.7 M
Slightly volatile
Net Receivables514.8 K316.2 K368.1 K
Slightly volatile
Common Stock Shares Outstanding3.1 M3 M755.2 K
Slightly volatile
Liabilities And Stockholders Equity33.1 M42.6 M25.8 M
Slightly volatile
Non Current Liabilities Total152.9 K161 K525.5 K
Slightly volatile
Other Current Assets93.2 K98.1 K1 M
Very volatile
Other Stockholder Equity214.5 M204.3 M80.3 M
Slightly volatile
Total Liabilities4.5 M4.7 M3.7 M
Slightly volatile
Total Current Assets20 M10.2 M14.7 M
Slightly volatile
Short Term Debt381 K329.4 K669.1 K
Slightly volatile
Property Plant And Equipment Net400.1 K331.2 K259.3 K
Slightly volatile
Non Current Assets Total34 M32.3 M12.3 M
Slightly volatile
Property Plant And Equipment Gross400.1 K331.2 K259.3 K
Slightly volatile
Other Liabilities124 K130.5 K308.9 K
Pretty Stable
Net Tangible Assets24 M30.2 M20 M
Slightly volatile
Short Term Investments1.2 M1.3 M9.8 M
Very volatile
Property Plant Equipment451.2 K784.3 K327.4 K
Slightly volatile
Net Invested Capital39.4 M37.8 M24.4 M
Slightly volatile
Net Working Capital5.4 M5.7 M11.3 M
Slightly volatile
Intangible Assets33.6 M32 M10.8 M
Slightly volatile
Capital Lease Obligations156.5 K164.7 K308.5 K
Pretty Stable
Non Currrent Assets Other136.8 K144 K2 M
Slightly volatile
Other Assets136.8 K144 K2 M
Slightly volatile
Good Will24.6 M32.2 M22.3 M
Slightly volatile

Purple Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense298.6 K514 K247.9 K
Slightly volatile
Selling General Administrative4.6 M3.4 M3.6 M
Slightly volatile
Other Operating Expenses12.5 M12.7 M9.9 M
Slightly volatile
Research Development7.6 M8.8 M5.8 M
Slightly volatile
Interest Income337.9 K299 K248.8 K
Slightly volatile
Minority Interest33.3 K35.1 K700.1 K
Slightly volatile
Reconciled Depreciation170.4 K213.9 K97.1 K
Slightly volatile
Cost Of Revenue224.6 K213.9 K48.3 K
Slightly volatile
Selling And Marketing Expenses308.7 K369.1 K265.4 K
Slightly volatile

Purple Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities10.9 M7.8 M8.7 M
Pretty Stable
Stock Based Compensation635.8 K669.3 K999.1 K
Slightly volatile
End Period Cash Flow8.4 M8.5 M6.4 M
Slightly volatile
Begin Period Cash Flow8.4 M16.7 M6.5 M
Slightly volatile
Depreciation136.7 K213.9 K94 K
Slightly volatile
Issuance Of Capital Stock5.1 M5.2 M5.4 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio92.33132146
Slightly volatile
Dividend Yield0.0880.10.1119
Slightly volatile
Days Sales Outstanding366210263
Pretty Stable
Stock Based Compensation To Revenue8.2211.0114.5214
Slightly volatile
Capex To Depreciation0.01660.01751.8063
Slightly volatile
EV To Sales63.4449.04103
Slightly volatile
Payables Turnover0.04030.03840.0104
Slightly volatile
Sales General And Administrative To Revenue23.2328.4539.9206
Slightly volatile
Research And Ddevelopement To Revenue82.2178.352.6309
Slightly volatile
Capex To Revenue0.01670.01760.0776
Slightly volatile
Cash Per Share0.0180.0191.7966
Slightly volatile
Days Payables Outstanding9.4 K9.9 K4.7 M
Slightly volatile
Income Quality1.871.780.8676
Slightly volatile
Intangibles To Total Assets0.360.680.4506
Slightly volatile
Current Ratio1.912.014.3514
Pretty Stable
Receivables Turnover1.110.771.0595
Slightly volatile
Capex Per Share0.00.00.0037
Slightly volatile
Revenue Per Share9.0E-49.0E-40.0128
Pretty Stable
Interest Debt Per Share4.0E-44.0E-42.7275
Slightly volatile
Debt To Assets0.00540.00570.6962
Slightly volatile
Days Of Payables Outstanding9.4 K9.9 K4.7 M
Slightly volatile
Ebt Per Ebit1.20.761.0652
Pretty Stable
Quick Ratio1.912.014.7615
Pretty Stable
Net Income Per E B T0.951.140.9152
Pretty Stable
Cash Ratio2.892.132.1793
Pretty Stable
Days Of Sales Outstanding366210263
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.80.90.9857
Slightly volatile
Fixed Asset Turnover0.460.483.7257
Pretty Stable
Debt Ratio0.00540.00570.6962
Slightly volatile
Price Sales Ratio92.33132146
Slightly volatile
Asset Turnover0.00480.00510.0136
Very volatile

Purple Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap17.9 M9.5 M18.3 M
Slightly volatile

Purple Fundamental Market Drivers

Purple Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
21st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Purple Biotech Financial Statements

Purple Biotech shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Purple Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Purple Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Purple Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.1 M1.2 M
Cost Of Revenue213.9 K224.6 K
Stock Based Compensation To Revenue 11.01  8.22 
Sales General And Administrative To Revenue 28.45  23.23 
Research And Ddevelopement To Revenue 78.30  82.21 
Capex To Revenue 0.02  0.02 
Ebit Per Revenue(102.37)(97.25)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Purple Stock Analysis

When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY